Episode 12. ASH 2022 Myeloma Recap

1. GEM-CESAR and ASCENT Trials: Intensive Treatment Strategy in High-Risk Smoldering Multiple Myeloma

https://ash.confex.com/ash/2022/webprogram/Paper159606.html

https://ash.confex.com/ash/2022/webprogram/Paper168930.html

2. What are the odds of having BMPC≥10% in a person with MGUS? IstopMM answers this question by developing a prediction model.

https://ash.confex.com/ash/2022/webprogram/Paper170166.html

Link to the model: https://istopmm.com/riskmodel/

3. RCT comparing Rd (continuous) vs Rd induction-Mel140-AHCT-R Maintenance in transplant-eligible older adults (60-75 years) with newly diagnosed multiple myeloma 

https://ash.confex.com/ash/2022/webprogram/Paper159357.html

4. Talquetamab: Phase 1/2 results from Monumental-1

https://tinyurl.com/kwn9en9m

https://www.nejm.org/doi/full/10.1056/NEJMoa2204591

5. MALDI-TOF Mass Spect for Monoclonal Free Light Chain Assessment: A promising candidate for MRD testing in AL amyloidosis

https://tinyurl.com/yrvjjruv

6. Randomized Phase IV REAL Trial (VMP vs Rd) in New Diagnosed Transplant-Ineligible Myeloma

https://tinyurl.com/bde84xuw

7. Teclistamab-Daratumumab-Lenalidomide combination in earlier lines of therapy: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

https://ash.confex.com/ash/2022/webprogram/Paper159711.html

8. Three excellent abstracts from IstopMM:

Is MGUS associated with autoimmune disease?

https://tinyurl.com/5dafcz2w

Is isolated hypercalcemia in a person with MGUS worrisome for transformation into myeloma?

https://tinyurl.com/4tut3rea

Is MGUS associated with CKD?

https://tinyurl.com/34swvkj9

9. Outcome of patients with high-risk cytogenetic abnormalities in a secondary analysis of MASTER and Dara-VRD arm of GRIFFIN trials

https://tinyurl.com/2n78yzfh

10. Surrogacy between PFS and OS in Multiple Myeloma

https://ash.confex.com/ash/2022/webprogram/Paper163855.html

https://pubmed.ncbi.nlm.nih.gov/36495317/